Clinical Trial Update: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sotorasib plus panitumumab and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb as first-line therapy for metastatic colorectal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab-awwb (bevacizumab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Panitumumab (panitumumab)
• sotorasib (sotorasib)

Snippet

Sponsor: Amgen | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: RECRUITING